AGM questions for submission to management, page-11

At the NWR Conference in late March, Wayne said the pivotal trial will enroll 500-1100 patients and that he expects it to be enrolled in a year. That would mean the trial will take 2 years since each patient will be followed for a year. He also said that the company will be reimbursed $25,000 USD for each DurAVR used in the trial so that will obviously offset the cost by $12.5 million to $27.5 million depending on the number of patients enrolled.

He hasn't given any guidance on the number of sites for the pivotal trial that I can remember but I expect more than 20.

You can watch that conference here: https://anteristech.com/us/en/home/newsandevents.html

I posted my expectations about the pivotal trial timeline here if you'd like to take a look at that:
https://hotcopper.com.au/threads/ann-quarterly-activities-appendix-4c-cash-flow-report.7344517/?post_id=67442112&embed=1